Surface modified nanofibrous scaffolds for ocular surface repair

Biodegradable PLGA scaffolds with micro-perforations and ECM proteins address the limitations of current biological scaffolds, offering a reliable and immune-compatible solution for LSCD treatment by promoting cell proliferation and maintaining optical clarity.

WO2026236239A1PCT designated stage Publication Date: 2026-11-12NORTH CAROLINA STATE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026719
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current biological scaffolds for treating Limbal Stem Cell Deficiency (LSCD) suffer from batch-to-batch variability, limited supply, and potential immune rejection, necessitating a more reliable and compatible alternative.

Method used

Development of biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffolds with micro-perforations and functionalized with recombinant extracellular matrix proteins like Collagen IV and Laminin-521, designed for ocular surface repair, supporting cell attachment, proliferation, and differentiation.

Benefits of technology

The PLGA scaffolds provide a scalable, immune-compatible platform for LSC transplantation, enhancing cell proliferation and differentiation, and maintaining optical clarity for ocular surface regeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026719_12112026_PF_FP_ABST
    Figure US2026026719_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Described herein are electrospun Poly Lactide-co-Glycolic Acid (PLGA) scaffolds for ocular surface regeneration, including the treatment of Limbal Stem Cell Deficiency (LSCD). The scaffolds support attachment, proliferation, and maintenance of induced pluripotent stem cell- derived limbal stem cells (iPSC-LSCs). In embodiments, the scaffold surface was functionalized with extracellular matrix proteins, specifically Collagen IV and / or Laminin-521, through atmospheric plasma treatment. Microperforations were introduced using laser cutting to improve transparency and mechanical properties. The scaffolds described herein can be used for iPSC-LSC transplantation, advancing regenerative therapies for ocular surface disorders.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. 035051 / 651628SURFACE MODIFIED NANOFIBROUS SCAFFOLDS FOR OCULAR SURFACE REPAIRBACKGROUND

[0001] The cornea, a transparent, avascular tissue located at the front of the eye, is fundamental to vision due to its role in refracting light and acting as a protective barrier. It consists of five layers, including the epithelium, stroma, and endothelium, with the outermost epithelium being in constant turnover, maintained by a unique population of unipotent stem cells called limbal stem cells (LSCs). These LSCs reside in the limbus, bordering corneal circumference, separating the cornea from the conjunctiva, and are essential for the regeneration of the corneal epithelium.

[0002] Damage to these LSCs, either through chemical bums, infections, or autoimmune disorders, leads to a condition known as Limbal Stem Cell Deficiency (LSCD), which severely impairs corneal regeneration. LSCD results in a range of complications, including corneal opacification, vascularization, and scarring, all of which culminate in visual impairment or complete blindness. LSCD presents a significant clinical challenge, as the body is unable to regenerate the comeal epithelium without functional LSCs.

[0003] One of the most promising treatment strategies for LSCD is the transplantation of healthy LSCs to restore comeal surface integrity. However, this therapeutic approach hinges on the development of a suitable carrier or scaffold to deliver these cells to the affected cornea. The scaffold must not only provide structural support but also offer an environment conducive to cell survival, proliferation, and differentiation. Currently, biological scaffolds derived from natural tissues, such as amniotic membrane, collagen, or fibrin, are commonly employed in clinical settings. While these materials exhibit good biocompatibility and have been successfully used in comeal regeneration, they present several limitations, including batch-to-batch variability, limited supply, and the potential for immune rejection.

[0004] What is therefore needed are scaffold materials that address these shortcomings.BRIEF SUMMARY

[0005] Described herein are biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffolds comprising, at least one layer comprising a plurality of electrospun fibers, a plurality of micro-1LEGAL / 51215767vlAttorney Docket No. 035051 / 651628perforations in at least one surface of the layer, and at least one recombinant extracellular matrix protein associated with the layer.

[0006] In certain embodiments are methods for ocular surface wound repair by contacting an ocular surface of a subject with an effective amount of a PLGA scaffold as described herein.

[0007] In certain embodiments are methods for ocular surface regeneration by contacting an ocular surface of a subject with an effective amount of a PLGA scaffold comprising stem cells as described herein.

[0008] In certain embodiments are methods for treating LSCD in a subject by contacting a surface of the eye of the subject with an effective amount of a PLGA scaffold comprising stem cells as described herein.

[0009] In certain embodiments are methods for preparing a PLGA scaffold comprising, electrospinning a solution of PLGA the prepare a layer comprising a plurality of electrospun fibers, microperforating at least one surface of the layer to form microperforations in the layer, optionally subjecting the layer comprising microperforations to plasma treatment, and associating at least one recombinant extracellular matrix protein with the plasma treated layer comprising mi croperforati ons .

[0010] In certain embodiments are sealed containers comprising a biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffold comprising, at least one layer comprising a plurality of electrospun fibers, a plurality of micro-perforations in at least one surface of the layer, and at least one recombinant extracellular matrix protein associated with the layer.

[0011] Other embodiments are also described.BRIEF DESCRIPTION OF FIGURES

[0012] Figure 1 shows an exemplary process for scaffold fabrication, post modification, and seeding with iPSC-LSCs to prepare scaffolds for the treatment of LSCD.

[0013] Figure 2A-G shows fabrication and laser perforation of electrospun scaffold. A) SEM image showing fibers prior to perforation. B-C) Optical micrograph after perforation at 100 pm (B) and 50 pm (C) spacing. D) Transparency of non-perforated scaffold. E-F) Transparency of perforated scaffold demonstrated using photography at 100 pm (E) and 50 pm (F) spacing. G) Percent transmittance of light at different wavelengths through the scaffolds.2LEGAL / 51215767vlAttorney Docket No. 035051 / 651628

[0014] Figure 3A-B shows surface characterization of plasma treated PLGA scaffolds. A) ToF-SIMS imaging showing overlay of Col-IV shown as lighter areas on PLGA shown in darker areas. B) Immunofluorescence staining of Col-IV (lighter areas).

[0015] Figure 4A-B shows cell viability and proliferation of iPSC-LSC at different time points on treated or untreated PLGA scaffolds. (A) Live / Dead staining of iPSC-LSC where the first column shows stained cells indicated as live cells. The second column, row DI and D3 are an approximately 50:50 mix of live and dead cells, and row D5 and D7 are approximately 95% dead cells. The third column, row DI is approximately 95% live cells, and rows D3, D5, and D7 are approximately 95% dead cells. The fourth column, row DI is approximately 90% live cells, row D3 is approximately 50:50 mix of live and dead cells, row D5 and D7 are approximately 95% dead cells. The fifth column, all rows are approximately 95% live cells. The sixth column, rows DI, D3, and D5 are approximately 95% live cells, and row D7 is approximately 90% live cells. Representative images shown here. Scale bar: 275 pm. (B) Proliferation of iPSC-LSC on scaffolds at different time points. The error bars represent SEM and **** denotes statistical significance at p < 0.0001 between the control and PLGA-Plasma treated+Ln-521 at each timepoint using two-way analysis of variance followed by Tukey's multiple comparison post hoc test.

[0016] Figure 5A-B shows morphology of iPSC-LSC on various scaffolds. (A) Staining of F-actin using to visualize cytoskeleton of iPSC-LSC on scaffold at Day 7. Representative images shown here. Scale bar: 100 pm. (B) Representative Scanning Electron Microscopy images of iPSC-LSC on scaffolds at Day 7. Scale bar: 20 pm.

[0017] Figure 6A-B shows expression of iPSC-LSC markers at Day 7. (A) Expression of ANp63 and PAX6 where the fourth column shows a merged image of the first three columns. In row 1 (Ln-521 coated TCP), approximately 70% of the cells express ANp63 and PAX6. In row 2 (PLGA-Plasma treated + Ln-521), approximately 90% of the cells express ANp63 and PAX6. In row 3 (PLGA-Plasma treated + Ln-521 + Col-IV), approximately 80% of the cells express ANp63 and approximately 90% of cells express PAX6. (B) Expression of CK12 and ABCG2 where the fourth column shows a merged image of the first three columns. In row 1 (Ln-521 coated TCP), approximately 15% of the cells express CK12 and approximately 95% of the cells express ABCG2. In row 2 (PLGA-Plasma treated + Ln-521), approximately 5% of the cells express CK12 and approximately 90% of the cells express ABCG2. In row 3 (PLGA-Plasma treated + Ln-521 + Col-3LEGAL / 51215767V1Attorney Docket No. 035051 / 651628IV), approximately 5% of the cells express CK12 and approximately 90% of the cells express ABCG2. Representative images shown here. Scale bar: 100 pm.

[0018] Figure 7 shows gene expression analysis for LSC related markers in iPSC-LSC seeded on various scaffolds on Day 7. The left bar in each set is Ln-521 Coated TCP; the middle bar is PLGA-Plasma treated + Ln-521; the right bar is PLGA-Plasma treated + Ln-521 + Col-IV. The error bars represent SEM and statistical significance were determined using two-way analysis of variance followed by Tukey's multiple comparison post hoc test.

[0019] Figure 8 shows the elongation at break comparison of PLGA scaffolds A, B, and C.

[0020] Figure 9 shows the ultimate tensile strength comparison of PLGA scaffolds A, B, and C.

[0021] Figure 10 shows the average elongation at break comparison between thinner PLGA scaffolds and thicker PLGA scaffolds.

[0022] Figure 11 shows the average ultimate tensile strength comparison between thinner PLGA scaffolds and thicker PLGA scaffolds.

[0023] Figure 12 shows the average Modulus comparison between thinner PLGA scaffolds and thicker PLGA scaffolds.DETAILED DESCRIPTION

[0024] Described herein are synthetic scaffolds designed to address the limitations associated with existing biological-based scaffolds. The synthetic scaffolds are amenable to scale-up, do not rely on tissue supplies and provide a reliable platform for LSC transplantation in the treatment of LSCD and other ocular surface disorders. The scaffold is based on Poly Lactide-co-Glycolic Acid (PLGA), a biodegradable and biocompatible polymer that has been widely studied in tissue engineering and regenerative medicine. PLGA is attractive for this application due to its adjustable degradation rate, mechanical stability, and ease of processing. Its degradation rate can be tailored by altering the ratio of lactide to glycolide, which allows for precise control over the duration of scaffold support in vivo.

[0025] Despite its favorable mechanical properties and biodegradability, PLGA is inherently hydrophobic and lacks the bioactive cues necessary for optimal cell-material interactions. These characteristics can limit the scaffold’s ability to support cell adhesion and proliferation, particularly for sensitive cell types such as LSCs. To address these limitations, surface functionalization techniques are employed to modify the scaffold and enhance its biocompatibility.4LEGAL / 51215767V1Attorney Docket No. 035051 / 651628The PLGA scaffold was then capable of being functionalized with one or more extracellular matrix proteins, specifically Collagen IV and / or Laminin-521, both of which play critical roles in maintaining the stem cell niche in the limbus. Collagen IV and Laminin 521 are human recombinant isoforms that are well characterized and commercially available. See, Penton, C., et al., Skeletal Muscle, 6; 44, Dec 2016); Polisetti, N., et al., Scientific Reports, 7, 5152 (2017); Stepp, M., Experimental Eye Res., 83 (1), 3-13 (July 2006); Kabosova, A., et al., Investigative Ophthalmology & Visual Science, 48, 49989-49999 (Nov. 2007). Collagen IV is a key structural component of the basement membrane, while Laminin-521 supports stem cell adhesion, survival, and differentiation. By immobilizing these proteins onto the scaffold surface, the microenvironment of the limbal niche is replicated, providing bioactive sites that promote the attachment and maintenance of LSCs. Although Collagen IV is the most abundant protein in ocular surface tissues, unexpectedly the plasma treated PLGA scaffold functionalized with only Laminin-521 has a relative cell proliferation at least 2x greater than a plasma treated PLGA scaffold functionalized with Collagen IV or functionalized with both Collagen IV + Laminin-521. These experimental results support the use of the PLGA scaffolds described herein as an alternative to amniotic membranes for ocular surface regeneration and as a method for treating LSCD.

[0026] Another consideration in the design of a scaffold for ocular surface regeneration is transparency. Since the cornea is responsible for transmitting and focusing light, any scaffold used in its repair must maintain a high degree of optical clarity. Traditional electrospun scaffolds, while highly porous, are not inherently transparent due to the random arrangement of fibers, which can scatter light and reduce transmittance. To overcome this issue, micro-scale perforations were designed to provide transparency but also retain strength in each dimension. Engineered perforations were incorporated into the electrospun PLGA scaffold using a picosecond laser cutting technique. This method allows for the precise creation of micro-pores without causing significant damage to the surrounding scaffold structure.

[0027] Described herein, the efficacy of the surface-modified, micro-perforated electrospun PLGA scaffold was evaluated for ocular wound repair, to facilitate ocular surface regeneration, and as a treatment for LCSD in supporting the attachment, proliferation, and differentiation of iPSC-derived LSCs (iPSC-LSCs) in vitro. iPSC-derived LSCs offer several advantages over traditional donor-derived LSCs, including the potential for autologous transplantation, which eliminates the risk of immune rejection, as well as the ability to generate large numbers of cells 5LEGAL / 51215767vlAttorney Docket No. 035051 / 651628for therapeutic use. Furthermore, iPSCs can be derived from the patient’s own cells, paving the way for personalized medicine approaches to ocular surface regeneration.

[0028] The presently disclosed subject matter will now be described more fully hereinafter. However, many modifications and other embodiments of the presently disclosed subject matter set forth herein will come to mind to one skilled in the art to which the presently disclosed subject matter pertains having the benefit of the teachings presented in the foregoing descriptions. Therefore, it is to be understood that the presently disclosed subject matter is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein covers all alternatives, modifications, and equivalents. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in this field. All publications, patent applications, patents and other references mentioned herein are incorporated by reference into their entirety.Definitions

[0029] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the present application and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein. The terminology used in the description of the invention herein is for the purpose of describing particular aspects only and is not intended to be limiting of the invention. In case of a conflict in terminology, the present specification is controlling.

[0030] As used herein, the term “and / or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).

[0031] The term “or” refers to any one member of a particular list.6LEGAL / 51215767vlAttorney Docket No. 035051 / 651628

[0032] Unless otherwise apparent from the context, the term “about” encompasses values within a standard margin of error of measurement (e.g., SEM) of a stated value or variations ± 0.5%, 1%, 5%, or 10% from a specified value.

[0033] The singular forms of the articles “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a protein” or “at least one protein” can include a plurality of proteins, including mixtures thereof.

[0034] Compositions or methods “comprising” or “including” one or more recited elements may include other elements not specifically recited. For example, a composition that “comprises” or “includes” a protein may contain the protein alone or in combination with other ingredients.

[0035] As used herein, the term “scaffold” refers to a biodegradable polymer for biomedical purposes. The “scaffold” can used in tissue engineering, serving as a 3D structure to support cell growth, proliferation, and differentiation. The “scaffold” can be made from a synthetic fibrous material, such as PLGA according to methods described herein.

[0036] As used herein, the term “Poly Lactide-co-Glycolic Acid” or “PLGA” refers to a biodegradable and biocompatible copolymer that is made from the polymerization of lactic acid (LA) and glycolic acid (GA). PLGA has an adjustable degradation rate, mechanical stability, and ease of processing. Different forms of PLGA can be obtained depending on the ratio of lactide to glycolide used for the polymerization. PLGA can be used to make “electrospun” scaffolds, which can be further functionalized with various “ECM” protein combinations.

[0037] As used herein, the terms “extracellular matrix” or “ECM” protein refer to a diverse group of molecules that form the non-cellular component of tissues and organs. They provide structural support, adhesion, and signaling cues for cells.

[0038] As used herein, the term “plurality” refers to a number more than one, or a number greater than one.

[0039] As used herein, the term “transparent” or “transparency” refers to a property of a scaffold whereby sufficient light passes through so that objects are visible through the scaffold. Transparency can be reported in percentages, wherein 0% transparency refers to 0% of light passing through the scaffold, and 100% transparency refers to 100% of light passing through the scaffold. The “light” can be of any wavelength between 300 nm and 850 nm.

[0040] As used herein, the terms “plasma treated” and “plasma treatment” refer to presenting bioactive, hydrophilic functional groups to cell culture materials, which improves cell adhesion 7LEGAL / 51215767V1Attorney Docket No. 035051 / 651628and viability. Atmospheric “plasma treatment” is a technology that utilizes a partially ionized gas, known as plasma, to modify the surface properties of materials at ambient pressure. Activating the scaffold surface through plasma treatment allowed for uniform and higher attachment of ECM proteins.

[0041] As used herein, the term “cell proliferation” refers to the process by which cells increase in number through growth and division.

[0042] As used herein, the term “contacting” or “contact” and the like refers to physical communication. In some embodiments, “contact” refers to suturing of the scaffold to an ocular surface.

[0043] As used herein, the term “surface of the eye” or “ocular surface” and the like refers to all anatomy of the eye, not limited to the cornea, the tears, the conjunctiva, and the margin of the eye lids. In particular embodiments, the surface of the eye comprises the cornea or is primarily the cornea.

[0044] As used herein, the term “Limbal Stem Cell” or “LSC” refers to a unipotent stem cell which maintains the outermost “epithelium” layer of the “cornea.” LSCs reside in the limbus, bordering corneal circumference, separating the cornea from the conjunctiva, and are essential for the regeneration of the corneal epithelium.

[0045] As used herein, the term “Limbal Stem Cell Deficiency” or “LSCD” refers to damage of LSCs, either through chemical bums, infections, or autoimmune disorders, which severely impairs comeal regeneration. LSCD results in a range of complications, including corneal opacification, vascularization, and scarring, all of which culminate in visual impairment or complete blindness.

[0046] As used herein, the term “induced pluripotent stem cell-derived limbal stem cell” or “iPSC-LSC” refers to a stem cell derived from adult cells which are reprogrammed to an embryonic-like state. iPSC-derived LSCs offer several advantages over traditional donor-derived LSCs, including the potential for autologous transplantation, which eliminates the risk of immune rejection, as well as the ability to generate large numbers of cells for therapeutic use. Furthermore, “iPSCs” can be derived from a patient’s own cells.

[0047] As used herein, the term “Collagen IV” or “Col-IV” refers to a human recombinant “extracellular matrix” or “ECM” protein that plays a key structural component of the basement membrane. Col-IV was procured from Sigma-Aldrich, St. Louis, MO, USA. All Col-IV molecules are composed of three polypeptide chains arranged in a triple helical conformation, with a structure 8LEGAL / 51215767vlAttorney Docket No. 035051 / 651628that can be a repeating motif with glycine in every third position and proline or 4-hydroxyproline frequently preceding the glycine residue.

[0048] As used herein, the term “Laminin-521” or “Ln-521” refers to a full-length human recombinant “extracellular matrix” or “ECM” protein that is essential for iPSC-LSC attachment and survival and is known to support stem cell adhesion, survival, and differentiation. Ln-521 was procured from Biolamina, Sundbyberg, Sweden and confirmed to be a trimeric protein of about 774 kDa total molecular weight in non-reducing SDS-PAGE.

[0049] As used herein, the term “electrospinning” refers to a versatile technique used to produce nanofibrous materials with a high surface-area-to-volume ratio. “Electrospun” scaffolds exhibit a morphology that closely mimics the natural “extracellular matrix” (ECM) of tissues, providing a three-dimensional environment that is favorable for cell attachment, migration, and differentiation.

[0050] As used herein, the term “1,1, 1,3, 3, 3-hexafluoro-2 -propanol” or “HFIP” refers to a polar, hydrogen bond-donating, fluorinated alcohol used as a solvent and synthetic intermediate, particularly in organic chemistry.

[0051] As used herein, the term “nanofiber” refers to fibers with diameters in the nanometer range that can be created using various techniques, including “electrospinning” conditions.

[0052] As used herein, the term “laser perforation” or “perforation” or “micro-perforation” and the like refers to holes in a layer of the electrospun scaffolds. The “micro-perforations” can span a partial or full depth of a surface of the PLGA layer, a full depth of multiple PLGA layers, or the full depth of the PLGA scaffold. Microscale perforations in the electrospun scaffold will improve transparency, porosity, and gas transport. Additionally, it will provide another additional layer of control on mechanical and degradation properties.

[0053] As used herein, the term “scanning electron microscopy” or “SEM” refers to a technique that uses a focused beam of electrons to create high-resolution images of a sample's surface, revealing its topography and chemical composition. SEM can be used on a wide variety of materials and show images with details at the nanometer scale.

[0054] As used herein, the term “ToF-SIMS” refers to time-of-flight secondary ion mass spectrometry.

[0055] As used herein, the term “RT-qPCR” refers to real-time quantitative polymerase chain, which can be used to analyze relative gene expression.9LEGAL / 51215767vlAttorney Docket No. 035051 / 651628

[0056] As used herein, the term “TCP” refers to tissue culture plastic, which is standard disposable plastic ware to support mammalian cell culture.

[0057] As used herein, the term “phalloidin staining” refers to a technique used to analyze the morphology of “iPSC-LSC” which allows for visualization of actin filaments, also known as “F-actin”

[0058] As used herein, the term “wound repair” refers to the process by which the body restores damaged tissue after an injury. Described herein are scaffolds and methods for applying scaffolds as “wound repair” materials to improve and / or accelerate ocular healing.

[0059] As used herein, the term “hole spacing” refers to a distance between one or more holes in a plurality of holes in the PLGA scaffold generated by laser micro-perforations. The hole spacing is determined by the laser, for example in a designed pattern. As used herein, the term “designed pattern” refers to a pre-determined array of laser micro-perforations, as opposed to a random spacing of the holes.

[0060] As used herein, the term “ocular surface regeneration” refers to the process of repairing or restoring damaged tissue on the surface of the eye, including the cornea. Ocular surface regeneration can be achieved by contacting the damaged area with the PGLA scaffolds described herein.

[0061] As used herein, the term “effective amount” refers to an amount of the PLGA scaffold described herein that is effective for treating ocular surface wound repair, ocular surface regeneration, and / or LSCD. Those of skill in this filed are able to routinely determine an effective amount for the clinical indications of interest.

[0062] As used herein, the term “associated with” means that the ECM protein(s) is bound to the PLGA scaffold through physical adsorption, such as electrostatic or hydrophobic interactions, and covalent conjugation. Plasma treatment of the PLGA scaffold can increase surface hydrophilicity, which allows for more uniform coating of the PLGA with ECM proteins.

[0063] As used herein, the term “relative cellular proliferation” refers to the total number of cells observed through growth and division on a PLGA scaffold, compared to a baseline and / or other PLGA scaffolds. In some embodiments, the cellular proliferation on a PLGA scaffold with one ECM protein may be much higher relative to the cellular proliferation on a PLGA scaffold with a different ECM protein.10LEGAL / 51215767vlAttorney Docket No. 035051 / 651628Compositions and Methods

[0064] Provided are compositions of iPSC-LCS supported PLGA scaffold biomaterials for ocular surface regeneration, particularly in the treatment of LSCD. Compositions comprising PLGA scaffolds developed in this study are described. The biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffolds comprising, at least one layer comprising a plurality of electrospun fibers, a plurality of micro-perforations in at least one surface of the layer, and at least one recombinant extracellular matrix protein associated with the layer.

[0065] In some embodiments, the PLGA scaffold comprises about a 10:1 ratio of DL-lactide and glycolide. In some embodiments, the PLGA scaffold comprises about 5:1 ratio of DL-lactide and glycolide. In some embodiments, the PLGA scaffold comprises about 2:1 ratio of DL-lactide and glycolide. In some embodiments, the PLGA scaffold comprises about a 1:10 ratio of DL-lactide and glycolide. In some embodiments, the PLGA scaffold comprises about 1:5 ratio of DL-lactide and glycolide. In some embodiments, the PLGA scaffold comprises about 1:2 ratio of DL-lactide and glycolide. In some embodiments, the PLGA scaffold comprises about a 1 : 1 ratio of DL-lactide and glycolide. In some embodiments, the fibers of the PLGA scaffold have an average fiber diameter of about 0.5-3.0 pm. In some embodiments, the fibers of the PLGA scaffold have an average fiber diameter of about 1.0-2.5 pm. In some embodiments, the fibers of the PLGA scaffold have an average fiber diameter of about 1.561-1.953 pm. In some embodiments, the microperforations comprise a plurality of holes. In some embodiments, the holes have a diameter of about 50-300 pm. In some embodiments, the holes have a diameter of about 100-250 pm. In some embodiments, the holes have a diameter of about 200 pm. In some embodiments, the plurality of holes is in a designed pattern where the hole spacing is from about 5 pm to about 200 pm apart. In some embodiments, the plurality of holes is in a designed pattern where the hole spacing is from about 40 pm to about 60 pm apart. In some embodiments, the plurality of holes is in a designed pattern where the hole spacing is from about 50 pm to about 100 pm apart. In some embodiments, the plurality of holes is in a designed pattern where the hole spacing is from about 80 pm to about 120 pm apart. In some embodiments, the scaffold is transparent. In some embodiments, the light transmittance is about 30-80%. In some embodiments, light transmittance is about 44-60%.

[0066] In some embodiments, the biodegradable PLGA scaffold comprising, at least one layer comprising a plurality of electrospun fibers, a plurality of micro-perforations in at least one surface of the layer, and at least one recombinant extracellular matrix protein associated with the layer has 11LEGAL / 51215767vlAttorney Docket No. 035051 / 651628been plasma treated. Tn some embodiments, the at least one recombinant ECM associated with the layer is Laminin-521. In some embodiments, the at least one recombinant ECM associated with the layer is Laminin-521 and further comprises Collagen IV. In some embodiments, the at least one recombinant ECM consists essentially of Laminin-521 and of Collagen IV. In some embodiments, the at least one recombinant ECM consists essentially of Laminin-521 and does not comprise Collagen IV.

[0067] In some embodiments, the biodegradable PLGA scaffold comprising, at least one layer comprising a plurality of electrospun fibers, a plurality of micro-perforations in at least one surface of the layer, and at least one recombinant extracellular matrix protein associated with the layer has been plasma treated and further comprises a plurality of stem cells. In some embodiments, the stem cells comprise a plurality of iPSC-LSCs. In some embodiments, the at least one recombinant ECM consists essentially of Laminin-521 and does not comprise Collagen IV. In some embodiments, the biodegradable PLGA scaffold comprising, at least one layer comprising a plurality of electrospun fibers, a plurality of micro-perforations in at least one surface of the layer, and at least one recombinant extracellular matrix protein associated with the layer has been plasma treated and further comprises a plurality of stem cells wherein the at least one recombinant ECM protein consists essentially of Laminin-521 has a relative cell proliferation greater than a scaffold surface wherein the ECM protein comprises Collagen IV. In some embodiments, the scaffold surface wherein the at least one recombinant ECM protein is Laminin-521 has a relative cell proliferation at least or about 2x greater than a scaffold surface wherein the at least one recombinant ECM protein comprises Collagen IV.

[0068] In some embodiments, the biodegradable PLGA scaffold comprising, at least one layer comprising a plurality of electrospun fibers, a plurality of micro-perforations in at least one surface of the layer, and at least one recombinant extracellular matrix protein associated with the layer has been plasma treated and further comprises a plurality of iPSC-LSCs express a plurality of LSC markers related to sternness and corneal epithelial lineage. In some embodiments, the LSC markers are selected from the group consisting of PAX6, CEBPd, ABCG2, ABCB5, p63, CK3, CK14, and Involucrin (IVL). In some embodiments, the iPSC-LSCs on the scaffold surface express p63.

[0069] In some embodiments, the biodegradable PLGA scaffolds described herein comprise at least one layer comprising a plurality of electrospun fibers, wherein each layer has a thickness of about 150-1000 pm. In some embodiments, the at least one layer has a thickness of about 150- 12LEGAL / 51215767V1Attorney Docket No. 035051 / 651628800 pm. In some embodiments, each layer of the at least one layer has a thickness of about 150- 400 pm. In some embodiments, each layer of the at least one layer has a thickness of about 150- 210 pm. In some embodiments, each layer of the at least one layer has a thickness of about 250- 350 pm. In some embodiments, each layer of the at least one layer has a thickness of about 300- 700 pm. In some embodiments, each layer of the at least one layer has a thickness of about 400- 600 pm. In some embodiments, each layer of the at least one layer has a thickness of about 400- 1000 pm. In some embodiments, each layer of the at least one layer has a thickness of about 500-800 pm. In some embodiments, the PLGA scaffold comprises multiple layers, wherein the layers are disposed on top of each other and the scaffold has a total thickness of about 300-1000 pm. In some embodiments, the scaffold comprises two to six layers. In some embodiments, the scaffold comprises two, three, four, five or six layers.

[0070] In some embodiments, the biodegradable PLGA scaffolds described herein have an elongation at break of 95-350%. In some embodiments, PLGA scaffolds with a thickness of 150-300 pm have an elongation at break of 150-350%. In some embodiments, PLGA scaffolds with a thickness of 150-200 pm have an elongation at break of 150-350%. In some embodiments, PLGA scaffolds with a thickness of 200-300 pm have an elongation at break of 180-331%. In some embodiments, PLGA scaffolds with a thickness of 150-300 pm have an elongation at break of 150-350% and a UTS of 2.5-6.0 Mpa. In some embodiments, PLGA scaffolds with a thickness of 150-300 pm have an elongation at break of 150-350%, a UTS of 2.5-6.0 Mpa, and a Modulus of 44-93. In some embodiments, PLGA scaffolds with a thickness of 390-550 pm have an elongation at break of 95-305%. In some embodiments, PLGA scaffolds with a thickness of 390-400 pm have an elongation at break of 95-305%. In some embodiments, PLGA scaffolds with a thickness of 490-550 pm have an elongation at break of 215-265%. In some embodiments, PLGA scaffolds with a thickness of 390-550 pm have an elongation at break of 95-305% and a UTS of 1.5-3.5 Mpa. In some embodiments, PLGA scaffolds with a thickness of 390-550 pm have an elongation at break of 95-305% a UTS of 1.5-3.5 Mpa, and a Modulus of 14-80.

[0071] In some embodiments, the biodegradable PLGA scaffolds described herein have a UTS of 1.5-6.0 Mpa. In some embodiments, PLGA scaffolds with a thickness of 150-300 pm have a UTS of 2.5-6.0 Mpa. In some embodiments, PLGA scaffolds with a thickness of 150-200 pm have a UTS of 4.9-6.0 Mpa. In some embodiments, PLGA scaffolds with a thickness of 200-300 pm have a UTS of 2.6-5.2 Mpa. In some embodiments, PLGA scaffolds with a thickness of 150-300 pm 13LEGAL / 51215767vlAttorney Docket No. 035051 / 651628have a UTS of 2.5-6.0 Mpa and a Modulus of 44-93. In some embodiments, PLGA scaffolds with a thickness of 390-550 pm have a UTS of 1.5-3.5 Mpa. In some embodiments, PLGA scaffolds with a thickness of 390-400 pm have a UTS of 1.5-3.5 Mpa. In some embodiments, PLGA scaffolds with a thickness of 490-550 pm have a UTS of 2.8-3.3 Mpa. In some embodiments, PLGA scaffolds with a thickness of 390-550 pm have a UTS of 1.5-3.5 Mpa and a Modulus of 14-80.

[0072] In some embodiments, the biodegradable PLGA scaffolds described herein have a Modulus of 14-95. In some embodiments, PLGA scaffolds with a thickness of 150-300 pm have a Modulus of 44-95. In some embodiments, PLGA scaffolds with a thickness of 150-200 pm have a Modulus of 80-95. In some embodiments, PLGA scaffolds with a thickness of 200-300 pm have a Modulus of 44-95. In some embodiments, PLGA scaffolds with a thickness of 390-550 pm have a Modulus of 14-80. In some embodiments, PLGA scaffolds with a thickness of 390-400 pm have a Modulus of 14-45. In some embodiments, PLGA scaffolds with a thickness of 490-550 pm have a Modulus of 75-80.

[0073] Provided are methods for ocular surface wound repair by contacting an ocular surface of a subject with an effective amount of a PLGA scaffold described herein. In some embodiments, contacting an ocular surface comprises placing the scaffold in physical communication with the ocular surface without suturing. In some embodiments, contacting an ocular surface comprises suturing the scaffold to the ocular surface.

[0074] Provided are methods for ocular surface regeneration by contacting an ocular surface of a subject with an effective amount of the stem cell supported PGLA scaffolds described herein. In some embodiments, the stem cells comprise a plurality of iPSC-LSCs. In some embodiments, the method for ocular surface regeneration by contacting an ocular surface of a subject with an effective amount of iPSC-LSC containing PLGA scaffold is a PLGA scaffold wherein the at least on ECM protein consists essentially of Laminin-521 and does not comprise Collagen IV. In some embodiments, contacting an ocular surface comprises placing the scaffold in physical communication with the ocular surface without suturing. In some embodiments, contacting an ocular surface comprises suturing the scaffold to the ocular surface. In some embodiments, the sutures are vicryl (polyglactin 910) sutures, USP sizes: 4-0 or 9-0. In some embodiments, the PLGA scaffolds described herein comprising micro-perforations and a thickness of about 150-1000 pm are sutured to the ocular surface. In some embodiments, the PLGA scaffold sutured to 14LEGAL / 51215767vlAttorney Docket No. 035051 / 651628the ocular surface does not comprise micro-perforations. In some embodiments, the subject has Limbal Stem Cell Deficiency (LSCD). In some embodiments, the subject has undergone a keratectomy. In some embodiments, the subject has a scleral wound or corneal abrasion.

[0075] Provided are methods for treating LSCD by contacting a surface of the eye of the subject with an effective amount of the iPSC-LSC containing PGLA scaffolds described herein. Provided are methods for preparing a PLGA scaffold comprising electrospinning a solution of PLGA to prepare a layer comprising a plurality of electrospun fibers, microperforating at least one surface of the layer to form microperforations in the layer, optionally subjecting the layer comprising microperforations to plasma treatment, and associating at least one recombinant extracellular matrix protein with the plasma treated layer comprising microperforations. In some embodiments, the microperforating is obtained by laser microperforation of the layer in a designed pattern. In some embodiments, the method further comprises, after said associating, seeding the layer by contacting the layer with a plurality of iPSC-LSCs. In some embodiments, the method further comprises, prior to said seeding, sterilizing the layer and washing the layer. In some embodiments, preparing an electrospun PLGA scaffold comprises a needle collector distance of about 10-20 cm. In some embodiments, preparing an electrospun PLGA scaffold comprises a needle tip of about 18-22 G. In some embodiments, preparing an electrospun PLGA scaffold comprises a voltage applied to the needle tip of about 10-30 kV applied voltage. In some embodiments, preparing an electrospun PLGA scaffold comprises a flow rate of about 1-6 mL / hr. In some embodiments, the layer of the PLGA scaffold has a thickness of about 150-1000 pm. In some embodiments, the PLGA further comprises one or more layers.

[0076] In certain embodiments are sealed containers comprising a biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffold comprising, at least one layer comprising a plurality of electrospun fibers, a plurality of micro-perforations in at least one surface of the layer, and at least one recombinant extracellular matrix protein associated with the layer. In some embodiments, the sealed container comprises a biodegradable PLGA scaffold where the scaffold has an area from about 0.01 cm2to less than about 5 cm2, or less than about 3 cm2, or less than about 1.5 cm2. In some embodiments, the sealed container comprises a PLGA scaffold where the scaffold comprises a plurality of stem cells. In some embodiments, the stem cells comprise a plurality of induced pluripotent stem cell-derived limbal stem cells (iPSC-LSCs). In some embodiments, the sealed15LEGAL / 51215767vlAttorney Docket No. 035051 / 651628container further comprises a liquid, such as saline and / or excipients, such as a preservative. Such excipients are known in the field.

[0077] The subject matter described herein includes, but is not limited, to the following embodiments:1. A biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffold comprising, at least one layer comprising a plurality of electrospun fibers;a plurality of micro-perforations in at least one surface of the layer; and,at least one recombinant extracellular matrix protein associated with the layer; optionally,wherein the at least one layer comprising a plurality of electrospun fibers comprises one to six layers.2. The scaffold of embodiment 1, wherein the PLGA scaffold comprises from about 10:1 to about 1:10 ratio of DL-lactide and glycolide.3. The scaffold of embodiment 2, wherein the fibers of the PLGA scaffold have an average fiber diameter of about 0.5-3.0 pm.4. The scaffold of embodiment 1, wherein the micro-perforations comprise a plurality of holes.5. The scaffold of embodiment 4, wherein the holes have a diameter of about 50 to about 300 pm.6. The scaffold of embodiment 4, wherein the plurality of holes is in a designed pattern, wherein hole spacing is from about 5 pm to about 200 pm.7. The scaffold of embodiment 1, wherein the scaffold is transparent.8. The scaffold of embodiment 7, wherein the light transmittance is about 30-80%.9. The scaffold of embodiment 1, wherein the surface is plasma treated.10. The scaffold of embodiment 1, wherein the at least one extracellular matrix protein is Laminin-521.11. The scaffold of embodiment 10, further comprising Collagen IV.12. The scaffold of embodiment 10, wherein the extracellular matrix protein consists essentially of Laminin-521 and Collagen IV.13. The scaffold of embodiment 10, wherein the at least one extracellular matrix protein consists essentially of Laminin-521, and the scaffold does not comprise Collagen IV.16LEGAL / 51215767vlAttorney Docket No. 035051 / 65162814. The scaffold of embodiment 1, further comprising a plurality of stem cells.15. The scaffold of embodiment 14, wherein the stem cells comprise a plurality of induced pluripotent stem cell-derived limbal stem cells (iPSC-LSCs).16. The scaffold of embodiment 15, wherein the extracellular matrix protein consists essentially of Laminin-521, and the scaffold does not comprise Collagen IV.17. The scaffold of embodiment 16, wherein the relative cellular proliferation is at least or about 2x greater compared to a scaffold surface comprising Collagen IV.18. The scaffold of embodiment 15, wherein the iPSC-LSCs express a plurality of LSC markers related to sternness and corneal epithelial lineage.19. The scaffold of embodiment 18, wherein the LSC markers are selected from the group consisting of, PAX6, CEBPd, ABCG2, ABCB5, p63, CK3, CK14, and Involucrin (IVL).20. The scaffold of embodiment 18, wherein the iPSC-LSCs express p63.21. The scaffold of embodiment 1, wherein the layer has a thickness of about 150-1000 pm; or the layer has a thickness of about 150-800 pm.22. The scaffold of embodiment 21, wherein the at least one layer comprising a plurality of electrospun fibers comprises one to six layers; and optionally each layer has a thickness of about 150-1000 pm.23. A method for ocular surface wound repair comprising, contacting an ocular surface of a subject with an effective amount of a scaffold of any one of embodiments 1-22.24. The method of embodiment 23, wherein contacting comprises placing the scaffold in physical communication with the ocular surface without suturing.25. The method of embodiment 23, wherein contacting comprises suturing the scaffold to the ocular surface.26. A method for ocular surface regeneration comprising, contacting an ocular surface of a subject with an effective amount of a scaffold of embodiment 14.27. The method of embodiment 26, wherein the stem cells comprise a plurality of induced pluripotent stem cell-derived limbal stem cells (iPSC-LSCs).28. The method of embodiment 26 or 27, wherein the extracellular matrix protein consists essentially of Laminin-521, and the scaffold does not comprise Collagen IV.29. The method of embodiment 26, wherein contacting comprises placing the scaffold in physical contact with the ocular surface without suturing.17LEGAL / 51215767vlAttorney Docket No. 035051 / 65162830. The method of embodiment 26, wherein contacting comprises suturing the scaffold to the ocular surface.31. The method of embodiment 23 or 26, wherein the subject has Limbal Stem Cell Deficiency (LSCD).32. The method of embodiment 23 or 26, wherein the subject had a keratectomy.33. The method of embodiment 23 or 26, wherein the subject has a scleral wound or corneal abrasion.34. A method for treating LSCD in a subject comprising, contacting a surface of the eye of the subject with an effective amount of a scaffold of embodiment 14.35. A method for preparing a PLGA scaffold, comprising:electrospinning a solution of PLGA to prepare a layer comprising a plurality of electrospun fibers;microperforating at least one surface of the layer to form microperforations in the layer;optionally subjecting the layer comprising microperforations to plasma treatment; and, associating at least one recombinant extracellular matrix protein with the plasma treated layer comprising microperforations.36. The method of embodiment 35, wherein the microperforating is obtained by laser microperforation of the layer in a designed pattern.37. The method of embodiment 35, further comprising:after said associating, seeding the layer by contacting the layer with a plurality of iPSC-LSCs.38. The method of embodiment 37, further comprising:prior to said seeding, sterilizing the layer; and,washing the layer.39. The method of embodiment 35, wherein a needle collector distance is about 10-20 cm.40. The method of embodiment 35, wherein a needle tip is about 18-22 G.41. The method of embodiment 35, wherein a voltage applied to the needle tip is about 10- 30 kV applied voltage.42. The method of embodiment 35, wherein a flow rate is about 1 mL / hr to about 6 mL / hr.18LEGAL / 51215767vlAttorney Docket No. 035051 / 65162843. The method of embodiment 35, wherein the layer has a thickness of about 150- 1000 pm.44. The method of embodiment 43, wherein PLGA scaffold further comprises one or more additional layers.45. A sealed container comprising:a biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffold, said scaffold comprising:at least one layer comprising a plurality of electrospun fibers;a plurality of micro-perforations in at least one surface of the layer; and,at least one recombinant extracellular matrix protein associated with the layer.46. The sealed container of embodiment 45, wherein the biodegradable PLGA scaffold has an area at least or about 1.3 cm2.47. The container of embodiment 45, wherein the biodegradable PLGA scaffold further comprises a plurality of stem cells.48. The container of embodiment 47, wherein the stem cells comprise a plurality of induced pluriprotent stem cell-derived limbal stem cells (iPSC-LSCs).EXAMPLESExample 1: Morphology and Optical Properties of Scaffold

[0078] The schematic illustration of the experimental process is shown in Figure 1.

[0079] Poly Lactide-co-Glycolic Acid (PLGA) (50:50 ratio; Purasorb® PDLG 5010; Corbion Amsterdam, Netherlands) was used to make electrospun scaffolds. The electrospinning solution was created by dissolving PLGA (14% w / v) in l,l,l,3,3,3-hexafluoro-2-propanol (HFIP) (H0424; TCI America, Portland, OR, USA) by overnight magnetic stirring. The following electrospinning conditions was used to collect nanofibers on the stationary copper shim collector: 15 cm needle collector distance; 20 G needle tip; 16 kV voltage applied to needle tip, flow rate of 4 mL / hr.

[0080] The LPKF ProtoLaser R tool located at the Northwestern University Atomic and Nanoscale Characterization Experimental Center (NUANCE) or at the North Carolina State University Nanofabrication Facility was used to make laser perforation in the electrospun scaffolds. These microscale perforations in the electrospun scaffold will improve transparency, porosity, and gas transport. Additionally, it will provide another additional layer of control on mechanical and 19LEGAL / 51215767vlAttorney Docket No. 035051 / 651628degradation properties. The hole diameters were kept consistent at 100-200 pm with varying hole spacings 50 and 100 pm.

[0081] To measure light transmittance, the samples were cut into circles with a diameter of 6.5 mm and placed into wells of 96-well plate. The blank control was 100 pm of DPBS and 100 pm of DPBS was also added to each sample. The microplate reader (Synergy HT; BioTek, Winooski, Vermont, US) was used to determine the light transmittance of the constructs under wavelengths in the range between 400 nm and 750 nm.

[0082] Through successful optimization of electrospinning properties, electrospun membranes of consistent fiber diameter with random orientation were obtained (Figure 2A). Scaffold characterization from SEM images reveals an average fiber diameter of 1.757+0.196 pm. After fabrication of the electrospun membrane, perforations were introduced using picosecond laser cutter. The holes were introduced with minimal damage to the scaffold with desired diameter and spacing. The electrospun scaffolds were successfully perforated with holes of 200 pm and with varying distance of 100 pm (Figure 2B) or 50 pm (Figure 2C) between them. These perforations improve visibility as can be seen from the digital photograph when compared with non-perforated PLGA scaffold (Figure 2D-F). Visible light absorption spectra observed using microplate, shows that decreasing distance between perforations improved light transmittance from 44% to 60% (Figure 2G). Perforations can provide an additional layer of control on the mechanical and degradation properties of the developed scaffold while keeping the polymer and fabrication parameters consistent.Example 2: Surface Characterization of Scaffold

[0083] The electrospun PLGA scaffolds were functionalized with various ECM protein combinations: 1) 5 pg cm2Collagen-IV (Col-IV) (Col IV, Sigma-Aldrich, St. Louis, MO, USA), 2) 0.5 pg cm2Laminin-521 (Ln-521, Biolamina, Sundbyberg, Sweden), 3) Col-IV + LN-521 by overnight incubation at 4 °C. Plasma treatments were conducted with e-RioTM Atmospheric Pressure Plasma System Model APPR-D300-13 (APJeT, Inc. Santa Fe, New Mexico). It is a glowdischarge plasma reactor powered by radio frequency. Plasma treatment was conducted for 5 minutes at 300 W plasma power with 2 mm distance between electrode and sample on both sides of the sample. The plasma treatment chamber was supplied with a mixture of helium and oxygen20LEGAL / 51215767V1Attorney Docket No. 035051 / 651628(90:10). The plasma treated samples were immediately submerged in various ECM protein combinations as previously mentioned.

[0084] The samples were put into the ToF-SIMS and set under vacuum overnight prior to the analysis. ToF-SIMS analyses were conducted using a TOF SIMS V (ION TOF, Inc. Chestnut Ridge, NY) instrument equipped with a Binm+(n = 1 - 5, m = 1, 2) liquid metal ion gun, Cs+sputtering gun and electron flood gun for charge compensation. The analyzed surface area was 500 * 500 pm2for acquisition of mass spectral images.

[0085] To further ensure presence and bio functionality of the ECM proteins on the scaffold surface, immunostaining for ECM proteins were performed. The samples were washed with PBS thrice and blocked with 2% bovine serum albumin + 2% goat serum for 1 hour. Then the samples were incubated with primary antibodies overnight at 4°C. Later, the samples were washed with PBS and incubated with secondary antibodies at room temperature for 1 hour. Imaging was done using a fluorescent microscope (EVOS FL Auto 2; ThermoFisher). Antibodies used for this study are listed in Table 1.

[0086] Table 1. Antibodies used in immunofluorescence staining.Antibody Host Catalog N&. Manufacturer Dilution(vA)OCT 4 Goat AF1759 R&.D Systems 1 : 100Nanog Goat AF1997 R&D Systems 1:100Rabbit 4892 Cell Signaling 1:100 ABCG2 Rabbit ab229193 abeam 1:100 p40.ANp63 Mc®se ACI3066A BioCare Medical 1:100PAX6 Rribbit HPA030775 Sigma-Aldrich 1:100CKI2 Mouse sc-515882 Santa Cruz 1 : 100Anti-Goat alexa fluor 568 Donkey Al 1057 ThermoF isher 1:250Anti-rabbit alexa fluor 594 Goat Al 1012 TfaermoFisher 1:250Anti-mouse alexa fluor 488 Goat A21141 ThermoFisher 1:250Anti-rabbit alexa fluor 488 Goat Al 1008 ThermoFisher 1:250

[0087] Synthetic polymers such as PLGA have low cellular attachment due to its hydrophobic nature and low surface energy. Atmospheric plasma treatment provides quick and efficient method of functionalizing the surface of electrospun PLGA with ECM proteins without affecting the bulk properties. Compared to conventional method of coating cell culture surfaces, activating the surface through plasma treatment allowed uniform and higher attachment of ECM proteins on scaffold surfaces as evidenced by ToF-SIMS and antibody staining. From TOF-SIMS, it was observed that atmospheric plasma treatment allowed more homogenous and profuse covering with21LEGAL / 51215767vlAttorney Docket No. 035051 / 651628Col-TV compared to non-plasma treated (Figure 3 A). Col-IV immunostaining was also carried out to investigate the distribution and abundance of the covering (Figure 3B).Example 3: Viability and Proliferation of iPSC-LSC on Scaffold

[0088] Herein, iPSCs (iPS-DF19-9-7T, WiCell, Madison, WI) were used. The iPSCs were cultured on a 6 well plate (3506, Coming, Glendale, AZ, USA) coated as per the manufacturer’s instruction with LN-521 using E8 flex media (A2858501, ThermoFisher Scientific, Waltham, MA, USA). Differentiation towards LSC was done using a modified protocol (Abdalkader, R.; Kamei, K., Human Cell 2022, 35, 1016-1029). In brief, the iPSCs were plated at 1 x 104cell / cm2density on LN-521 coated plate with E8 media supplemented with 10 pM Y27632 dihydrochloride (1254, R&D Systems, Minneapolis, MN, USA). On the second day, the culture media was changed to E8 media only. For next 4 days, induction medium was used which consisted of E6 (A1516401, ThermoFisher) supplemented with Wnt pathway inhibitor (IWR-1 endo) (3532, R&D Systems) and TGF-P inhibitor (A83-01) (72024, STEMCELL Technologies, Cambridge, MA, USA) , and basic fibroblast growth factor (bFGF) (3718-FB-025, R&D Systems) at 2.5 pM, 10 pM, 50 ng / mL, respectively. Following plating, cells were maintained in E6 only media for 6 days to obtain differentiated iPSC-LSC prior to seeding them on the scaffolds. Prior to seeding iPSC-LSCs on the scaffolds, the scaffolds were sterilized by immersing in 70% ethanol for 30 minutes. After that, the scaffolds were washed with DPBS three times for 5 minutes each time. Then the samples were cut into 1x1 cm2before placing in the wells of a non-treated 24-well plate (10861-558, VWR, Radnor, PA, USA) with sterile stainless-steel washer (In Dia: 6.4 mm, Out Dia: 12 mm) placed on top of each sample. iPSC-LSCs were detached from 6-well plates using TrypLE™ Select Enzyme (12563029, ThermoFisher) after 10 days of differentiation and added to each well at a density of 0.1 x io5cells per scaffold. Wells coated with LN-521, with cells seeded at the same density, were used as the control. The culture was maintained in E6 media.

[0089] Both cell viability and proliferation assays were conducted on days 1, 3, 5 and 7 postseeding of iPSC-LSC (Mahmood, N.; Sefat, E.; Roberts, D.; Gilger, B. C.; Gluck, J. M., Translational vision science & technology 2023, 12, 15). In brief, cell viability was assessed using LIVE / DEAD™ Cell Imaging Kits (488 / 570) (R37601; ThermoFisher) at 1:4 dilution ratio with DPBS following the manufacturer’s recommendations. After a 25- minute incubation at 37 °C, imaging was conducted using a fluorescent microscope (EVOS FL Auto 2; ThermoFisher). For 22LEGAL / 51215767vlAttorney Docket No. 035051 / 651628measuring cell proliferation rates, alamarBlue™ Cell Viability Reagent (DALI 100; ThermoFisher) was used. iPSC-LSCs were washed once with DPBS prior to incubation with alamarBlue reagent diluted at a ratio of 1 : 10 v / v in cell culture medium for 3 hours at 37°C in the dark. Following incubation, supernatants were collected from each well and transferred to a 96-well plate (100 pL each well, 10861-666; VWR, Radnor, PA, USA). Fluorescence intensity was measured using a microplate reader (Synergy HT; BioTek, Winooski, Vermont, US) at 540 nm excitation and 590 nm emission wavelengths.

[0090] The experiments were conducted with at least three technical replicates and three biological replicates unless mentioned otherwise. All the data are presented as mean ± standard error of the mean unless indicated otherwise. Statistical analysis was carried out using GraphPad Prism version 9.4.1 for Windows (GraphPad Software, San Diego, CA, USA) by one or two-way analysis of variance followed by Tukey's multiple comparison post hoc test, and p < 0.05 was considered statistically significant and summarized as * = <0.05, ** = <0.01, *** = <0.0001 for the calculated p-values.

[0091] Adult stem cells such as LSCs are more sensitive to their surroundings as they reside in specialized microenvironments called "niches" within tissues, where the ECM plays a crucial role in maintaining their sternness and regulating their activity. The ability of electrospun PLGA scaffolds with different surface treatments were compared to support iPSC-LSC adherence, viability and proliferation. After 24 hours of seeding a viable cell population was observed on samples that were plasma treated and coated with Ln-521 and both Ln-521+ Col-IV (Figure 4A). For other plain and surface treatment conditions of PLGA, some iPSC-LSC adhered on the substrates, but many were stained as dead cells. From day 3 on these conditions, iPSC-LSCs detached from these substrates or were mostly stained as dead cells indicating their inability to support iPSC-LSC maintenance. Samples that were plasma treated and coated with Ln-521 and both Ln-521+ Col-IV could sustain iPSC-LSC culture for at least 7 days. A similar tread was observed when metabolic and proliferation activity of iPSC-LSCs was observed and quantified using an alamarBlue assay (Figure 4B). Plasma treated and coated with Ln-521 had the highest metabolic activity compared to all other conditions. Specifically, compared to Ln-521 coated TCP on Day 3 (p>0.001), Day 5 (p>0.0001), and Day 7 (p>0.001), there was significantly higher metabolic activity for plasma treated and coated with Ln-521. Plasma treated and coated with both Ln-521+ Col-IV also had higher metabolic activity compared to Ln-521 coated TCP. Subsequent 23LEGAL / 51215767vlAttorney Docket No. 035051 / 651628in vitro experiments were only performed on electrospun PLGA substrates that were plasma treated and coated with Ln-521 and both Ln-521+ CoLIV.Example 4: Morphology of iPSC-LSC on PLGA

[0092] To analyze the morphology of iPSC-LSC on scaffolds, both f-actin fdament staining and scanning electron microscopy (SEM) were utilized. iPSC-LSCs were fixed after 7 days of culture on scaffolds using 4% paraformaldehyde for 20 minutes and three washes with DPBS before and after. Permeabilization was carried out using 0.1% TritonX-100 for 15 minutes. Serum blocking was carried out using 2% bovine serum albumin + 2% goat serum for 1 hour. After that, iPSC-LSCs were stained with phalloidin (R37110; ThermoFisher) overnight at a concentration recommended by the manufacturer (2 drops / ml). Prior to imaging using fluorescent microscope, the iPSC-LSCs were washed with DPBS and counterstained with Hoechst 33342 (H3570, ThermoFisher). To prepare the scaffolds with iPSC-LSC for SEM imaging, the samples were first washed with DPBS thrice for 5 minutes each time followed by fixing with 4% paraformaldehyde for 20 minutes. DPBS washing step was repeated after fixing. Then, the samples were washed with 0.1M sodium cacodylate buffer (11652, Electron Microscopy Sciences) at pH 7.2 for 10 minutes, followed by fixation in a solution of 2% Paraformaldehyde / 2.5% Glutaraldehyde in 0.1M Sodium Cacodylate Buffer (15960-01, Electron Microscopy Sciences) for 30 minutes. Wash with 0.1M sodium cacodylate buffer at pH 7.2 for 10 minutes was repeated. The samples were dehydrated using gradually increasing concentrations of ethanol washes (35%, 50%, 70%, 80%, and 95%) for 10 minutes, followed by three 10- minutes washes in 100% ethanol, and a final 40- minutes wash in 100% ethanol. Following dehydration, drying was carried out using 50% ethanol and 50% HMDS (Hexamethyldisilazane) (50-243-18, Electron Microscopy Sciences) for 20 minutes, followed by 100% HMDS for an additional 20 minutes. The samples were mounted on SEM stubs with carbon adhesive and sputter coated (SC7620 Mini Sputter Coater; Quorum Technologies, East Sussex, UK) prior to examination using the Hitachi TM4000 SEM (Tokyo, Japan).

[0093] The samples were mounted on aluminum SEM stub carbon adhesive followed by sputtercoating (SC7620 Mini Sputter Coater; Quorum Technologies, East Sussex, UK) to achieve a layer of gold and palladium with a thickness of 10 nm prior to examination using the Hitachi TM4000 SEM (Tokyo, Japan).24LEGAL / 51215767vlAttorney Docket No. 035051 / 651628

[0094] Morphology of iPSC-LSC was analyzed using both phalloidin staining and SEM imaging. In all culture conditions, iPSC-LSC expressed polygonal epithelial like morphology and were densely packed with cytoskeletons connected with each other (Figure 5 A). Compared to Ln-521 coated TCP, iPSC-LSC cultured on PLGA surfaces appeared smaller. Further confirmation of tight cellular junction formation of iPSC-LSC on PLGA surfaces was observed through SEM imaging (Figure 5B) after 7 days of culture. Also, it was observed from the SEM images that iPSC-LSCs formed confluent multilayered cell sheets with strong adherence to the plasma treated PLGA substrates coated with Ln-521 or both LN-521 and Col -IV.Example 5: Sternness and Commitment Towards Corneal Epithelial Lineage iPSC-LSC on Scaffold

[0095] To investigate sternness and commitment towards corneal epithelial lineage, the expression of several proteins was analyzed using immunocytochemistry. The steps including fixing, permeabilizing, and blocking were carried out as described in the prior sections. Primary antibodies, diluted in blocking buffer, were applied and left to incubate overnight at 4°C. The following day, the samples were washed thrice with DPBS and incubated with the secondary antibody diluted in 10% blocking buffer for 1 hour at room temperature. Antibodies used for this study are listed in Table 1. Nuclei were counterstained with Hoechst 33342 and imaged with a fluorescent microscope.

[0096] To analyze relative gene expression, RT-qPCR was used. Total RNA was extracted and purified using Total RNA Purification Plus Micro Kit (48500, Norgen Biotek, ON, Canada) following the manufacturer’s instructions. The concentration and purity of the RNA was determined using Nanodrop (ND-ONE-W, ThermoFisher). Reverse-transcription was performed using High-Capacity cDNA Reverse Transcription Kit (4368814, ThermoFisher) as per the manufacturer’s instructions. The synthesized cDNA was then amplified and analyzed using TaqMan Gene Expression Assays (4331182, ThermoFisher), as listed in Table 2 using QuantStudio 3 (A28567, ThermoFisher) as per the manufacturer’s recommendations.

[0097] Table 2. List of TaqMan gene assay.25LEGAL / 51215767vlAttorney Docket No. 035051 / 651628Target genes Assay IDsGAPDH Hs 99999905_iu 1OCT4 HsO42«B67 gHPAX6 Hs00240871 mlCEBPd Hs00270931 siABCG2 HsO 1653790 mlABCB5 nilP63 Hs<J0978339 mlCK3 Hs00365074_mlCK14 Hs00265033 mlInvolucnn HsOOS46307 si

[0098] iPSC-LSC cultured on surface functionalized PLGA was investigated for maintaining their sternness and their commitment towards corneal epithelial lineage. iPSC-LSCs showed their characteristic epithelial-like morphology and formed confluent cell sheets on the surface functionalized electrospun scaffolds. This indicated preference of iPSC-LSC for the developed substrate and its suitability to act as a carrier for transplantation. The expression of several LSC markers were evaluated through immunocytochemistry (Figure 6). iPSC-LSC after 7-day culture on both surface modified PLGA and Ln-521 coated TCP strongly expressed markers related to sternness and used to identify LSCs (ANp63, ABCG2, PAX6). Faint and very low levels of CK12 were detected in all conditions. Analysis of relative gene expression reveals that compared to Ln-521 coated TCP, there was upregulation of LSC sternness marker p63, ABCG2, and CK14 on electrospun scaffolds (Figure 7). There was also upregulation in gene expression of CK3 and IVL, markers related to corneal epithelial differentiation and maturation on scaffolds surfaces compared to Ln-521 coated TCP. However, there was downregulation in expression oiABCB5 and CEBPd on scaffolds surfaces compared to Ln-521 coated TCP. This gene expression suggests heterogeneity of the LSCs with a prominent subpopulation of LSCs that are active and at an early transiently amplifying cell (TAC) stage of differentiation. Reported expression levels suggest that surface functionalized electrospun scaffolds could be used as carriers of iPSC-LSC for ocular surface reconstruction.Example 6: Suture Retention Test of PLGA Scaffolds

[0099] To investigate the suturability, PLGA scaffolds were sutured with vicryl (polyglactin 910) sutures, USP sizes: 4-0 or 9-0 and analyzed with MTS Q-test / 5 or MTS Criterion instrument (MTS Systems, Eden Prairie, MN, USA). Modified ASTM D3822 testing standards were used. Testing parameters involved a sample geometry of 12-14 mm circular discs, a bite length sutured in place 26LEGAL / 51215767vlAttorney Docket No. 035051 / 6516281.0 ± 0.2 mm from the scaffold edge, load cell of 10 N, ramping rate of 5 mm / min, gauge length of 12 ± 2 mm, grip pressure of 10 Psi, the upper grip avoided sandpaper at suture contact point, and the lower grip was a flat grip where the scaffold was clamped with at least 10 mm grip width. PLGA scaffolds of various thickness were investigated. Data show that thicker scaffolds are more resistant to tearing during suturing.Example 7: Tensile Strength of PLGA Scaffolds

[0100] To investigate the mechanical properties, PLGA scaffolds of various thickness were prepared. Scaffold A had a thickness of 180 pm and comprised a plurality of micro-perforations, wherein the micro-perforations comprised a plurality of holes. Each hole had a diameter of 200 pm with inter-hole spacing of 100 pm. Scaffold B had a thickness of 180 pm and comprised a plurality of micro-perforations, wherein the micro-perforations comprised a plurality of holes. Each hole had a diameter of 200 pm with inter-hole spacing of 50 pm. Scaffold C had a thickness of 300 pm and no micro-perforations.

[0101] The tensile strength of Scaffolds A, B, and C were analyzed with MTS Q-test / 5 or MTS Criterion instrument (MTS Systems, Eden Prairie, MN, USA). Testing parameters involved a modified ASTM D5O35 (Strip Method), load cell of 500 N, ramping rate of 5 mm / min, gauge length of 2.54 cm, 50% break sensitivity, and 10 Psi. The elongation at break (Figure 8) and ultimate tensile strength (Figure 9) was compared between Scaffolds A, B, and C (Figure 8). Scaffold A showed the highest ultimate tensile strength and better load-bearing capacity. Scaffold B failed at much lower elongation due to the higher hole density. Scaffold C had the longest elongation at break and the greatest ductility.

[0102] To further investigate the ultimate tensile strength (UTS) and modulus of PLGA scaffolds in relation to scaffold thickness, two groups of scaffolds were prepared. Group 1 represented a thinner scaffold and contained Scaffolds 1, 2, 3, and 4 (Table 3). The thinner scaffolds in Group 1 had a thickness between 150 pm and 300 pm, with an average thickness of 170 pm. Group 2 represented a thicker scaffold and contained Scaffolds 5, 6, 7, and 8 (Table 4). The thicker scaffolds in Group 2 had a thickness between 390 pm and 550 pm, with an average thickness of 460 pm. Data show the average elongation at break comparison (Figure 10), average ultimate tensile strength comparison (Figure 11), and average Modulus comparison (Figure 12) between thinner PLGA scaffolds and thicker PLGA scaffolds.27LEGAL / 51215767vlAttorney Docket No. 035051 / 651628

[0103] Table 3. Elongation at Break, UTS, and Modulus of thinner PLGA scaffolds.Group 1: Thinner ScaffoldsElongation atScaffold Thickness (pm) UTS (Mpa) Modulus Break (%)1 150 153.9 5.93 81.87 2 200 341.5 4.95 80.28 3 200 180.0 2.65 92.25 4 300 330.3 5.13 44.73 Average = 170 201.1 3.73 59.83SD = 60 98.2 1.41 20.73

[0104] Table 4. Elongation at Break, UTS, and Modulus of thicker PLGA scaffolds.Group 2: Thicker ScaffoldsElongation atScaffold Thickness (pm) UTS (Mpa) Modulus Break (%)5 390 301.7 3.38 43.62 6 400 95.7 1.58 14.21 7 490 263.0 3.27 78.32 8 550 215.0 2.89 75.32 Average = 460 218.9 2.78 52.87SD = 80 89.4 0.83 30.18

[0105] Herein described a substantial advancement in the development of biomaterials for ocular surface regeneration, particularly in the treatment of LSCD. While research has focused on using primary limbal stem cells on fibrous surfaces, this was the first study to examine iPSC-derived LSCs on an electrospun scaffold, opening new avenues for stem cell-based therapies. The electrospun PLGA scaffold developed in this study, with its enhanced surface properties through micro-perforations, plasma functionalization, and ECM protein coating, provides a more consistent and reliable platform for the attachment, proliferation, and maintenance of iPSC-LSCs compared to traditional natural scaffolds.

[0106] Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which the inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended 28LEGAL / 51215767vlAttorney Docket No. 035051 / 651628claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.29LEGAL / 51215767vl

Claims

Attorney Docket No. 035051 / 651628CLAIMSWhat is claimed is:

1. A biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffold comprising,at least one layer comprising a plurality of electrospun fibers;a plurality of micro-perforations in at least one surface of the layer; and, at least one recombinant extracellular matrix protein associated with the layer.

2. The scaffold of claim 1, wherein the PLGA scaffold comprises from about 10: 1 to about 1:10 ratio of DL-lactide and glycolide.

3. The scaffold of claim 2, wherein the fibers of the PLGA scaffold have an average fiber diameter of about 0.5-3.0 pm.

4. The scaffold of claim 1, wherein the micro-perforations comprise a plurality of holes.

5. The scaffold of claim 4, wherein the holes have a diameter of about 50 to about 300 pm.

6. The scaffold of claim 4, wherein the plurality of holes is in a designed pattern, wherein hole spacing is from about 5 pm to about 200 pm.

7. The scaffold of claim 1, wherein the scaffold is transparent.

8. The scaffold of claim 7, wherein the light transmittance is about 30-80%.

9. The scaffold of claim 1, wherein the surface is plasma treated.

10. The scaffold of claim 1, wherein the at least one extracellular matrix protein is Laminin- 521.

11. The scaffold of claim 10, further comprising Collagen IV.30LEGAL / 51215767vlAttorney Docket No. 035051 / 65162812. The scaffold of claim 10, wherein the extracellular matrix protein consists essentially of Laminin-521 and Collagen IV.

13. The scaffold of claim 10, wherein the at least one extracellular matrix protein consists essentially of Laminin-521, and the scaffold does not comprise Collagen IV.

14. The scaffold of claim 1, further comprising a plurality of stem cells.

15. The scaffold of claim 14, wherein the stem cells comprise a plurality of induced pluripotent stem cell-derived limbal stem cells (iPSC-LSCs).

16. The scaffold of claim 15, wherein the extracellular matrix protein consists essentially of Laminin-521, and the scaffold does not comprise Collagen IV.

17. The scaffold of claim 16, wherein the relative cellular proliferation is at least or about 2x greater compared to a scaffold surface comprising Collagen IV.

18. The scaffold of claim 15, wherein the iPSC-LSCs express a plurality of LSC markers related to sternness and corneal epithelial lineage.

19. The scaffold of claim 18, wherein the LSC markers are selected from the group consisting of, PAX6, CEBPd, ABCG2, ABCB5, p63, CK3, CK14, and Involucrin (IVL).

20. The scaffold of claim 18, wherein the iPSC-LSCs express p63.

21. The scaffold of claim 1, wherein the layer has a thickness of about 150-1000 pm.

22. The scaffold of claim 21, wherein the layer has a thickness of about 150-800 pm.31LEGAL / 51215767vlAttorney Docket No. 035051 / 65162823. A method for ocular surface wound repair comprising, contacting an ocular surface of a subject with an effective amount of a scaffold of any one of claims 1-22.

24. The method of claim 23, wherein contacting comprises placing the scaffold in physical communication with the ocular surface without suturing.

25. The method of claim 23, wherein contacting comprises suturing the scaffold to the ocular surface.

26. A method for ocular surface regeneration comprising, contacting an ocular surface of a subject with an effective amount of a scaffold of claim 14.

27. The method of claim 26, wherein the stem cells comprise a plurality of induced pluripotent stem cell-derived limbal stem cells (iPSC-LSCs).

28. The method of claim 26 or 27, wherein the extracellular matrix protein consists essentially of Laminin-521, and the scaffold does not comprise Collagen IV.

29. The method of claim 26, wherein contacting comprises placing the scaffold in physical contact with the ocular surface without suturing.

30. The method of claim 26, wherein contacting comprises suturing the scaffold to the ocular surface.

31. The method of claim 23 or 26, wherein the subject has Limbal Stem Cell Deficiency (LSCD).

32. The method of claim 23 or 26, wherein the subject had a keratectomy.

33. The method of claim 23 or 26, wherein the subject has a scleral wound or corneal abrasion.32LEGAL / 51215767vlAttorney Docket No. 035051 / 65162834. A method for treating LSCD in a subject comprising, contacting a surface of the eye of the subject with an effective amount of a scaffold of claim 14.

35. A method for preparing a PLGA scaffold, comprising:electrospinning a solution of PLGA to prepare a layer comprising a plurality of electrospun fibers;microperforating at least one surface of the layer to form microperforations in the layer;optionally subjecting the layer comprising microperforations to plasma treatment; and,associating at least one recombinant extracellular matrix protein with the plasma treated layer comprising microperforations.

36. The method of claim 35, wherein the microperforating is obtained by laser microperforation of the layer in a designed pattern.

37. The method of claim 35, further comprising:after said associating, seeding the layer by contacting the layer with a plurality of iPSC-LSCs.

38. The method of claim 37, further comprising:prior to said seeding, sterilizing the layer; and,washing the layer.

39. The method of claim 35, wherein a needle collector distance is about 10-20 cm.

40. The method of claim 35, wherein a needle tip is about 18-22 G.

41. The method of claim 35, wherein a voltage applied to the needle tip is about 10-30 kV applied voltage.33LEGAL / 51215767vlAttorney Docket No. 035051 / 65162842. The method of claim 35, wherein a flow rate is about 1 mL / hr to about 6 mL / hr.

43. The method of claim 35, wherein the layer has a thickness of about 150-1000 pm.

44. The method of claim 43, wherein PLGA scaffold further comprises one or more additional layers.

45. A sealed container comprising:a biodegradable Poly Lactide-co-Glycolic Acid (PLGA) scaffold, said scaffold comprising:at least one layer comprising a plurality of electrospun fibers;a plurality of micro-perforations in at least one surface of the layer; and, at least one recombinant extracellular matrix protein associated with the layer.

46. The sealed container of claim 45, wherein the biodegradable PLGA scaffold has an area at least or about 1.3 cm2.

47. The container of claim 45, wherein the biodegradable PLGA scaffold further comprises a plurality of stem cells.

48. The container of claim 47, wherein the stem cells comprise a plurality of induced pluriprotent stem cell-derived limbal stem cells (iPSC-LSCs).34LEGAL / 51215767V1